Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6TE7

The structure of CYP121 in complex with inhibitor S2

6TE7 の概要
エントリーDOI10.2210/pdb6te7/pdb
分子名称Mycocyclosin synthase, 2-chloranyl-4-[4-[(1~{R})-1-imidazol-1-ylprop-2-enyl]phenyl]phenol, TRIETHYLENE GLYCOL, ... (6 entities in total)
機能のキーワードcyp121, complex, inhibitor, oxidoreductase
由来する生物種Mycobacterium tuberculosis
タンパク質・核酸の鎖数1
化学式量合計44445.37
構造登録者
Adam, S.,Koehnke, J. (登録日: 2019-11-11, 公開日: 2021-05-26, 最終更新日: 2024-01-24)
主引用文献Walter, I.,Adam, S.,Gentilini, M.V.,Kany, A.M.,Brengel, C.,Thomann, A.,Sparwasser, T.,Kohnke, J.,Hartmann, R.W.
Structure-Activity Relationship and Mode-Of-Action Studies Highlight 1-(4-Biphenylylmethyl)-1H-imidazole-Derived Small Molecules as Potent CYP121 Inhibitors.
Chemmedchem, 16:2786-2801, 2021
Cited by
PubMed Abstract: CYP121 of Mycobacterium tuberculosis (Mtb) is an essential target for the development of novel potent drugs against tuberculosis (TB). Besides known antifungal azoles, further compounds of the azole class were recently identified as CYP121 inhibitors with antimycobacterial activity. Herein, we report the screening of a similarity-oriented library based on the former hit compound, the evaluation of affinity toward CYP121, and activity against M. bovis BCG. The results enabled a comprehensive SAR study, which was extended through the synthesis of promising compounds and led to the identification of favorable features for affinity and/or activity and hit compounds with 2.7-fold improved potency. Mode of action studies show that the hit compounds inhibit substrate conversion and highlighted CYP121 as the main antimycobacterial target of our compounds. Exemplified complex crystal structures of CYP121 with three inhibitors reveal a common binding site. Engaging in both hydrophobic interactions as well as hydrogen bonding to the sixth iron ligand, our compounds block a solvent channel leading to the active site heme. Additionally, we report the first CYP inhibitors that are able to reduce the intracellular replication of M. bovis BCG in macrophages, emphasizing their potential as future drug candidates against TB.
PubMed: 34010508
DOI: 10.1002/cmdc.202100283
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.50001818022 Å)
構造検証レポート
Validation report summary of 6te7
検証レポート(詳細版)ダウンロードをダウンロード

227344

件を2024-11-13に公開中

PDB statisticsPDBj update infoContact PDBjnumon